Research Article| Volume 20, SUPPLEMENT 3, C72-C79, 1998

Balancing risks versus benefits in drug therapy decisions

  • Louis Lasagna
    Address correspondence to: Louis Lasagna, MD, DSc, Director, Tufts Center for the Study of Drug Development, 192 South Street, Boston, MA 02111.
    Tufts Center for the Study of Drug Development, Boston, Massachusetts U.S.A.
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.


      The regulation of foods and drugs in the United States has repeatedly been increased in response to unjustified marketing claims or instances of dramatic harm from these substances. Because drugs are never safe or effective for everyone, the guiding principle for physicians should be to use pharmaceuticals in such a way as to maximize benefit and minimize harm.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Study cites adverse medication reactions in many patient deaths.
        The Boston Globe. 1998; (15): A8
        • Lazarus J
        • Pomeranz BH
        • Corey PN
        Incidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective studies.
        JAMA. 1998; 279: 1200-1205
        • Sinclair U
        The Jungle. Heritage Press, New York1965
        • Karch FE
        • Lasagna L
        Toward the operational identification of adverse drug reactions.
        Clin Pharmacol Ther. 1977; 21: 247-254
        • Bakke OM
        • et al.
        Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: A regulatory perspective.
        Clin Pharmacol Ther. 1995; 58: 108-117
        • Hippocrates
        Epidemics. W. Heinemann, London1923 (Book I, Sect. 12. Translation by Jones WHS)
        • Dans AL
        • Dans LF
        • Guyatt GH
        • Richardson S
        User's guides to the medical literature—XIV. How to decide on the applicability of clinical trial results to your patient.
        JAMA. 1998; 279: 545-549